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ABSTRACT
The observation that many people in Africa seek care for
febrile illness in the retail sector has led to a number of
public health initiatives to try to improve the quality of
care provided in these settings. The potential to support
the introduction of rapid diagnostic tests for malaria
(mRDTs) into drug shops is coming under increased
scrutiny. Those in favour argue that it enables the
harmonisation of policy around testing and treatment
for malaria and maintains a focus on market-based
solutions to healthcare. Despite the enthusiasm among
many global health actors for this policy option, there is
a limited understanding of the consequences of the
introduction of mRDTs in the retail sector. We
undertook an interpretive, mixed methods study with
drug shop vendors (DSVs), their clients and local health
workers to explore the uses and interpretations of
mRDTs as they became part of daily practice in drug
shops during a trial in Mukono District, Uganda. This
paper reports the unintended consequences of their
introduction. It describes how the test engendered trust
in the professional competence of DSVs; was
misconstrued by clients and providers as enabling a
more definitive diagnosis of disease in general rather
than malaria alone; that blood testing made drug shops
more attractive places to seek care than they had
previously been; was described as shifting treatment-
seeking behaviour away from formal health centres and
into drug shops; and influenced an increase in sales of
medications, particularly antibiotics.
Trial registration number: NCT01194557; Results.
INTRODUCTION
Across East Africa, urban and rural citizens’
use of retail outlets to access pharmaceutical
medicines to treat episodes of febrile illness
is well established.1–6 Current framings of the
global drive to control and eliminate malaria
often place this observation at the core
research agendas, programme ﬁnancing and
national decision-making processes.7
This interest in providing malaria medica-
tion through the retail sector has coincided
with a shift in global policy from the
presumptive treatment of all fevers as malaria
to the targeted treatment of parasitologically
conﬁrmed malaria, a policy to be realised in
large part through the introduction of a rapid
diagnostic test for malaria (mRDT).8 For
many, this has made the successful introduc-
tion of mRDTs into the retail sector impera-
tive.9 10 For others, the importance of
introducing mRDTs has been underscored by
the results of the Affordable Medicines Facility
Key questions
What is already known about this topic?
▸ Rapid diagnostic tests for malaria (mRDT) now
form a central element of malaria care.
▸ The scale-up of mRDTs through retail outlets is
being pursued by several governments in
Eastern and Southern Africa.
▸ Existing evaluations focus on the intended con-
sequences of mRDT use.
What are the new findings?
▸ This study examined the unintended conse-
quences of the introduction of mRDTs into
registered drug shops in Mukono, Uganda.
▸ The popularity of the tests appeared to be linked
to a rise in the status of drug shop vendors.
▸ Drug shops with mRDTs appeared more attract-
ive places to seek care, sales of medicines
increased and treatment seeking appeared to
shift out of the formal sector providers and into
these shops.
Recommendations for policy
▸ Policy makers need to be aware of the unintended
consequences of interventions before they decide
on whether they are appropriate or not. This is
especially the case in settings in which there is
little regulation and oversight of practice.
▸ If mRDTs are introduced into drug shops in
Uganda, a significant increase in surveillance
and supervision is likely to be necessary in
order to guard against poor quality, inequitable
practices that may increase out of pocket pay-
ments among those who can least afford them.
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for Malaria (AMFm) project, which sought to ﬂood private
sector markets with affordable, quality assured artemisinin
combination therapy (ACT), to crowd out less efﬁcacious
antimalarials.11 12 AMFm achieved its goal of improving
access through changes in the private for proﬁt sector, but
in so doing, it precipitated a substantial increase in the use
of ACTs among those who did not have malaria.13 This
raised concerns about the cost-effectiveness of the subsidy,
as well as whether it would favour the development and
spread of parasite resistance to artemisinin and risk the
future efﬁcacy of the drug.
Despite the fact that introducing mRDTs into private
sector markets appears a pragmatic solution to the
overuse of ACTs in retail outlets9 10 and has been enthusi-
astically taken up by many national-level and global-level
policymakers, studies on the impact of the mRDT have
shown varied results and been limited in scope.11 13 14 In
the retail sector in Kenya, while mRDTs were reported to
have been popular among clients, they did not substan-
tially reduce the numbers of ACTs sold to people who
tested negative.11 In Uganda, two studies reported that it
is feasible and safe to introduce mRDTs into registered
drug shops. In the ﬁrst study, the response to the intro-
duction of mRDTs was heterogeneous in terms of uptake
and adherence to test results.13 In the second study,
however, mRDTs were taken up enthusiastically by regis-
tered drug shop vendors (DSVs) and ACTs were appro-
priately targeted at 79% of patients in the mRDT arm as
opposed to 33.7% in the presumptive treatment arm.15
While these studies have been concerned with ascer-
taining whether and how mRDTs can be introduced, hol-
istic accounts that describe the mechanisms that their
successful introduction is based on and the unintended
consequences of their introduction are lacking. This con-
stitutes a considerable gap in the literature as all interven-
tions have impacts on society that cannot be foreseen and
which must be attended to in the overall evaluation of an
intervention.16 17 This is especially the case in places such
as drug shops that are poorly regulated and in which
poor practice is unlikely to be inﬂuenced or curtailed by
government policy and surveillance.
This paper adds to the literature on drug shops and
mRDTs by providing an anthropologically informed ana-
lysis of the unintended consequences of the introduction
of mRDTs into the retail sector in Uganda. It explores the
introduction of mRDTs into drug shops as a process of
assemblage, focusing on how mRDTs were arranged, orga-
nised and interacted with other objects, people, medi-
cines, desires, forms of regulation and everyday practice
found in drug shops in Mukono District. In so doing, the
paper shows that the popularity of mRDTs among both
DSVs and their clients was not a straightforward process of
the adoption of a technology that rationalised everyday
practice. Instead, we show how the use and popularity of
the test was intimately connected to local concerns about
the trustworthiness of DSVs, the quality of services on offer
in these shops, and the efﬁcacy of medicines and relation-
ship between drug shops and formal health providers.
Theoretical background
Anthropological approaches to evaluation, with a com-
mitment to inductive, holistic research, are well suited to
analysing the consequences of programmes beyond
those speciﬁed in proposals and protocols. It has been
suggested by Kleinman17 that this type of analysis is one
of the key contributions that medical anthropologists
can make to global health.18 19 His interest stems from
Merton’s original formulation of the unanticipated con-
sequences of purposive social action as the unforeseen
effects of actions with a motive, a choice among alterna-
tives, a goal and a process (such large-scale government
programmes, but also complex intervention trials).16 17
Merton offers several reasons for their emergence
including unforeseen shifts in context (such as ongoing
economic or social changes); the immediacy of the
interests of those formulating the programme; and the
institutional values that shape the thoughts of pro-
gramme managers or policymakers which make it hard
to see beyond their particular paradigm.16 While this
approach is useful in pointing to the complexity of intro-
ducing programmes to promote social change, it offers
relatively little in terms of understanding how local,
everyday practices shape interventions. Moreover, it
offers no means of understanding how interconnections
between the intended and unintended consequences of
an intervention may come about and, importantly for
this paper, how one may inﬂuence the other.
This paper draws on post-structuralist theories of the
microprocesses of sociomaterial relations, sometimes
referred to in the literature as theories of assemblage, to
better understand and develop an analysis of the unin-
tended consequences of introducing mRDTs into the
retail sector. Drawing on the French philosopher
Deleuze, these theories have been inﬂuential in anthro-
pology and sociology for their ability to account for the
interaction between society, science and technology and
local processes of social change.20 21 This gives ideas of
assemblage an obvious relevance to the analysis of the
introduction of mRDTs and also provides a pertinent
frame for understanding Ugandan drug shops more
generally. Like other ethnographic and social analyses of
drug sellers and informal private providers,22 23 the lit-
erature on Ugandan drug shops has shown these to be
spaces that provide an awkward mix of services, combin-
ing disparate elements from different social arenas and
in which those selling drugs do not necessarily adhere
to a single logic (biomedical or economic, scientiﬁc or
religious) but are more likely to draw on and display
forms of practice that come from multiple institutional
settings.3 24 Analyses that attend to the structural pos-
ition of drug sellers tend to present them as existing in
an odd and often insecure position, as liminal actors
occupying in an in-between social space.3 Post-structural-
ist accounts attend to the ways in which social ﬁelds are
assembled rather than structured and suggest that the
analyst shifts the focus. Instead of mapping the contra-
dictions that shoot through everyday practice, ﬁndings
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seek to account for the ways in which heterogeneous ele-
ments of the social and material world (from medicines,
to social norms, desires, people, buildings and illness)
come together and cohere, inﬂuencing and impacting
on one another.25
In terms of accounting for the intended consequences
of the introduction of mRDTs into drug shops, theories
of assemblage draw our attention to the ways in which
programmes or projects work by establishing relation-
ships between the mRDT and the use of malaria medi-
cines and that they fail when they do not. Yet, as this
intended relationship is established, relations between
the other social and material elements within the shop
emerge and it is these processes (sometimes quite self-
consciously arranged and organised by DSVs and their
clients) that create the unintended consequences of the
intervention.
A focus on the unintended consequences through the
lens of assemblage theories therefore makes the connec-
tions (or sociomaterial relations) between already exist-
ing elements of the drug shop and those that are put in
place through the actions of those implementing a
project or programme the key sites for analysis. Through
a focus on everyday practice, this paper analyses the pro-
cesses through which mRDTs became part of the assem-
blages that constitute the drug shops in Mukono.
Combining qualitative and quantitative data, it explores
three sets of connections that were key to shaping the
uses of the mRDT in the drug shops: local markets,
regulation, diagnosis and trust; blood tests, disease and
the generation of trust between DSV and their clients;
mRDTs, pharmaceutical markets and the desire for
effective medicine.
Study setting
Between October 2010 and December 2011, a cluster-
randomised trial was carried out in 59 registered drug
shops grouped into 20 geographical clusters in a periur-
ban area in Mukono, Uganda. Staff from 65 drug shops
had been invited to join the trial, though 6 shops failed
to attend the training and so were excluded. Following
invitation and consent to join the project, clusters of
drug shops were randomised to receive training in one
of two methods to diagnose malaria: 10 clusters were
trained to use clinical signs and symptoms (the pre-
sumptive arm), and 10 clusters were trained to use
mRDTs (the mRDT arm). All DSVs attended a 3-day
training in taking patient history, recognising malaria,
prescribing ACTs and rectal artesunate, when and how
to refer patients into the health service. In addition, the
DSVs in the intervention arm received an additional
day’s training on when and how to use an mRDT. DSVs
were also trained in record keeping and preparing
blood slides for the reference microscopy conducted on
each client, which were used by the trial to evaluate
whether the treatment decisions were appropriate or
not. All DSVs were given ACTs for free (artemether-
lumefantrine) to sell to patients at an agreed low retail
price (child: 1000 Uganda shilling, adult: 3000 Uganda
shilling, equivalent to US$0.40 and US$1.20, respect-
ively), disposable gloves, cotton wool, lancets, blood
slides, safety boxes for sharps disposal, triplicate carbon
copy patient registers for record keeping for the project,
and to provide a referral form should the client be con-
sidered too ill to be treated in the drug shop. All DSVs
in the mRDT arm were additionally provided with a con-
tinuous supply of mRDTs for free, and were asked to sell
these to patients at a ﬁxed price (500 Uganda shilling,
equivalent to US$0.20). The DSVs in the mRDT inter-
vention arm were provided with signs to place outside
their shop advertising the availability of mRDTs. In both
arms, community sensitisation through Village Health
Teams informed local residents about mRDTs underlin-
ing the fact that not all fevers are malaria; that it was
beneﬁcial to test for malaria before providing treatment
and that mRDTs were available locally from trained
DSVs and public health facilities. A detailed description
of the various elements of the intervention is provided
in the main trial paper.15
METHODS
Towards the end of the trial, between November 2011
and February 2012, research was undertaken to provide
an anthropologically informed, holistic account of the
intervention by exploring the processes and everyday
practices involved with the introduction and incorpor-
ation of mRDTs into drug shops and their affect on the
referral of clients from drug shops to other health facil-
ities. The research was particularly concerned with the
relationships between the different elements of the trial,
and the ways in which they impacted on the local
context of health seeking, the provision of healthcare
and the perception and experiences of conducting an
mRDT among providers and care seekers. The methods
used reﬂect the COREQ recommendations for qualita-
tive research26 and the relationships between the
researchers and the participants have been described in
detail elsewhere.27
Focus group discussions
Focus group discussions (FGDs) were conducted with
three subgroups: drug shop clients, DSVs and health
workers at local public facilities and a private not for
proﬁt hospital. In all, 21 FGDs were conducted (see
table 1) and each FGD had at least 5 and no more than
13 participants.
The participants were given a description of the
project when they were invited to participate in the
FGD. On the day of the FGD, the project was described
again and the participants were asked to sign a sheet to
consent in the research. They were advised that at any
point they could leave the FGD and that there was no
requirement for them to stay. Focus groups were con-
ducted in Luganda and/or English, and in all FGDs
notes were taken and the discussion recorded digitally.
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The FGDs were conducted in a Sunday school build-
ing except for two that were conducted at health facil-
ities. Each focus group was attended by three social
scientists acting as facilitator, note taker or organiser of
the session. The topics discussed were local treatment-
seeking behaviour, experiences at drug shops, experi-
ences with rapid diagnostic tests and experiences with
referral. The latter was a particular interest in the study
and this focus on referral from drug shops into public
sector health facilities was the reason behind the inclu-
sion of health workers from local health centres and
hospitals in the research. An emphasis was placed on
describing and understanding actual experience rather
than eliciting generalised or ideal statements. The facili-
tators also allowed conversations to develop between par-
ticipants when important but unanticipated themes
arose. Participants received money to cover the cost of
their travel and refreshments.
Recordings were transcribed, translated in English and
imported into Nvivo (QSR International, Cambridge,
Massachusetts, USA), a qualitative data analysis software
package for the aggregation of data by codes.
Coding and analysing qualitative data is an interpretive
endeavour and each FGD was coded by one social scien-
tist who had collected the data with close support and
supervision from the anthropologist (EH). A coding
scheme for each group was drawn up through a combin-
ation of themes emerging from the transcript coupled
with predeﬁned areas of interest identiﬁed from the
main intervention (mostly the interaction between dif-
ferent components of the trial) and from anthropo-
logical theory on informal health providers. The coding
scheme was adapted as necessary to reﬂect new themes
emerging and the anthropologist provided input at the
conceptual level of analysis. The main ﬁndings were dis-
cussed with the principal investigator of the main trial,
the anthropologist and the project’s social scientists
during a series of face-to-face meetings that took place
everyday over the course of a week.
Follow-up questionnaires
DSVs in all clusters recorded the names and contact
details of clients who visited their shops for a fever or
history of fever. Interviewers then visited DSVs according
to a randomised schedule to identify recent clients and
carried out questionnaire interviews (n=646) at the
client’s home after 4 days, and again between 10 and
14 days after visiting a drug shop. The questionnaires
were conducted to elicit reports on the economic costs
associated with treatment of the recent febrile episode
at a drug shop, whether they had been offered and had
accepted to be tested with an mRDT, their reported
results; the type and quantities of drugs purchased and
any subsequent costs over the next 10–14 days; and
exploring perceptions of mRDTs, their knowledge and
understanding of the tests, treatment-seeking behaviour
and referrals. For clients who were under 18, question-
naires were conducted with the adult who attended the
drug shop with the child; clients under 18 who attended
the DSV alone were excluded from the study. Clients
who did participate or consent to both questionnaires or
did not meet the overall study inclusion criteria were
excluded from the follow-up analysis. The analysis of
open questions was coded by CH using Nvivo (QSR
International, Cambridge, Massachusetts, USA) and,
where appropriate, imported into Stata V.13 (StataCorp
LP) and converted into ordinal or categorical variables
for descriptive quantitative analysis in conjunction with
quantitative responses.
Ethical clearance was granted by the London School
of Hygiene and Tropical Medicine and the Uganda
National Council for Science and Technology.
RESULTS
Context: diagnostic practice and the generation of trust
According to government policy, registered drug shops
are places in which over-the-counter medication may be
bought and sold. Legally, drug shops are distinct from
Table 1 Focus group discussions: numbers, participants, recruitment, stratification and exclusion criteria
DSV Health worker Drug shop client
Number of FGDs in
the RDT arm
4 5 4
Number of FGDs in
the presumptive arm
3 3 2
Total FGDs 7 8 6
Total FGD participants 54 71 54
Recruitment method From project records From visits to the health
facilities
From project records
Stratification By arm and frequency
of referral
By arm and level of
health facility
By referral for carers (for children) or adult
seeking care for febrile illness; or those who had
visited a shop for care for febrile illness
Exclusion criteria Those who had worked
in the area for
<6 months
Those who had worked
in the area for
<6 months
Those who had not visited a drug shop in the past
6 months, children under the age of 18
DSV, drug shop vendor; FGD, focus group discussion; RDT, rapid diagnostic test.
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private clinics and expected to provide a limited range
of products for sale, which excludes prescription medi-
cation such as antibiotics. In Mukono, however, categor-
ies of drug sellers were ﬂuid and clients were unable to
categorise private sector providers effectively during
FGDs. The ﬂuidity of this categorisation was also
reﬂected in the heterogeneous nature of the drug shops
in the trial. Most DSVs reported that they provided diag-
nostic advice and sales of medicine only but at least 2
out of the 59 study shops also offered in-patient services
and provided intravenous medication. At some, the
registered owner (who by law had to have some formal
biomedical training) would be in the shop for most of
its opening hours, providing relatively constant access to
a health provider.
As has been reported elsewhere among clients in
Uganda, the care seekers attending shops in Mukono
appreciated the good social relations often found in
these spaces3 but maintained a generalised suspicion of
DSVs’ motives and skills.27 DSVs could be respectful and
kind; attentive to the psychological, social and spiritual
needs of their clients; understanding of and responsive
to their economic constraints (providing of credit and
selling cheaper or incomplete doses) and keen to use
their skill and expertise. As one woman who had visited
a drug shop in the mRDT arm of the trial with her child
explained, these social relations often revolved around a
desire for powerful pharmaceutical drugs to manage
illness in them and in their children.
We had ﬁve thousand shillings (2 US$) in our pocket.
But because the sickness was severe, she wrote us a bill of
eighteen thousand shillings (7 US$). Yet, she had given
us a plenty of drugs in a polythene bag. Then I told her,
“I have come with ﬁve thousand [shillings],” and she
said, “Aha, there is no problem. You can even come back
tomorrow”, and she didn’t even know us…[later in the
discussion]…This health worker gives you drugs and you
also look at it and say, “as I have never seen such a quan-
tity of drugs!” and you simply say that. Oh, but the drugs
are worth the money you pay!
FGD with mothers in the mRDT arm of the trial
Attending a drug shop was also a risky act. Businesses
were infrequently visited by government regulators. In
all three groups of participants in the FGDs, the follow-
ing narratives echoed: drug shops are often run by those
who claimed expertise but had none, who knowingly
sold stolen, dangerous, expired or counterfeit drugs
and were only interested in making as large a proﬁt as
possible. Accounts of particular instances of receiving
poor quality care at drug shops and its consequences
for children’s health were commonplace. As previously
described by Birungi,28 injections were a popular form
of medicine, a sign of good care but raised particular
concerns about the infection and illness that could be
caused when unskilled DSVs administered injections to
small children. Moreover, in the context of ongoing con-
cerns about how to pay for treatment, clients expressed
concern that they could be overcharged for medication
by exploitative DSVs.
Where some FGD participants considered it to be
almost impossible to distinguish between skilled and
unskilled, trustworthy and untrustworthy DSVs, others
described how they acted to protect themselves against
the risks associated with attending a drug shop. Previous
treatment success, recommendations from neighbours
and the DSV’s diagnostic assessments played a central
role in identifying an effective, good quality and caring
provider. Below, a group of women described how they
evaluated a DSV’s skill through the questions that s/he
asked about the child’s symptoms.
P6: When you look there, when you are just passing by,
or maybe if you have had your child fall sick, some
people base [their assessment of a drug shop] on the way
the drug shop looks and then see whether they [the
DSVs] are skilled, drugs are in plenty. But, when you pass
there, [you may see that] the drugs that are there are
few. Now you can despise the place yet in the real, actual
sense she has the idea.
SS1: What do you mean by that thing of ‘idea’?
P2: What she wants to say is that she knows what she
does.
SS2: How can you come to know that someone is
knowledgeable?
P6: For me what I can explain, you can take a child and
you tell her, “Health worker, I feel the child has high
temperature.” You have not yet told her that it seems the
child is sick with malaria or what but for her she starts
asking you that…that is to say she knows the conditions
of children. Most of the time she asks you, “Has he done
this, do you feel his head is a bit hot (some high tem-
perature), how was he at night, did he at any time have
diarrhoea?” Okay things like that. That is to say, you have
not told her but she says correct things and you tell her,
“yes, health worker that is how it was”, before she mea-
sures his temperature to see the temperature…and she
asks you about the condition of the child, or how he was,
whether it is malaria or it is another thing.
FGD with mothers in the non-RDT arm
The diagnostic process underway in these drug shops
that existed prior to or without the introduction of
mRDTs had a productive role that went beyond the
imperative of identifying disease in order to provide
treatment. In this heterogeneous and poorly regulated
market, it was an important demonstration of medical
knowledge, and acted on the relationship between the
DSV and the client, engendering trust in a space in
which questions around motivation of the vendor and
the type of service that they provided were under con-
stant scrutiny.
mRDTs’ impact on decision-making about where to seek
care
According to the FGDs, mRDTs had not been available
in the drug shops in Mukono prior to the intervention
but when they were introduced, they were popular
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among DSVs and clients. Characteristics of the clients
interviewed on day 4 after drug shop consultation are
presented in table 2. Following refusal of consent (12)
and loss to follow-up (130), clients or carers comprised
251 who had visited a drug shop in the presumptive
diagnosis arm and 253 in the mRDT arm of the trial. In
both arms of the trial, half of those seeking care and
medication from a drug shop were children under the
age of 5, at 49.4% in the presumptive arm and 51.8% in
the mRDT arm. Of the 253 clients presenting with symp-
toms of a febrile illness in the mRDT arm, 97.6%
reported that they had purchased an mRDT. There were
occasional reports of mRDTs also being used in the pre-
sumptive arm (7/251 cases), ﬁndings that correspond to
those from the FGDs. This suggests that certain DSVs
were making the choice to purchase and offer these
tests for sale (see table 2).
Almost three-quarters of these care seekers in the
mRDT arm of the trial (72% of the 253 respondents)
reported in the questionnaires that they knew about the
availability of mRDTs prior to the recent visit to the
shop. Of those, the majority (73% of the 172 respon-
dents) considered that this had an impact on their
decision-making and why they had chosen to seek care
in a particular drug shop. During the FGDs, health
workers also noted changes in treatment-seeking
patterns.
P4: It [the introduction of mRDTs] has not affected us
badly because it has helped to reduce the number of
patients [that we see] and they [the DSVs] also get some
money…[laughter]…
P2: In my opinion, if a person has a sick child and they
go to the drug shop and they take off some blood in
Table 2 Characteristics of drug shop clients followed up and interviewed at home 4 days after the drug shop visit
Clients who visited drug shops
in the presumptive arm N=251
Clients who visited drug
shops in the RDT arm N=253
n Per cent n Per cent
Age of client (years)
0–1 28 11.2 42 16.6
1–5 96 38.2 89 35.2
5–18 75 29.9 54 21.3
18–45 40 15.9 49 19.4
45+ 12 4.8 19 7.5
Sex of participant
Female 137 54.6 122 48.2
Male 114 45.4 131 51.8
Role of respondent
Client (18+) 45 17.9 59 23.3
Mother 157 62.5 141 55.6
Head of household 19 7.6 22 8.7
Other guardian/carer* 30 12.0 31 12.3
Reported symptom(s)
Diarrhoea 23 9.2 23 9.2
Cough or influenza 93 37.0 90 35.7
Fever 130 51.8 115 45.6
Headache 57 22.7 50 19.8
Vomiting 19 7.6 34 23.5
Malaria 26 10.4 21 8.4
Went elsewhere before this DSV
Yes 107 42.6 114 45.1
No 140 55.8 128 50.6
Did not report anything 4 1.6 11 4.3
Purchased an mRDT
Yes 7 2.8 247 97.6
No 244 97.2 6 2.42
*Where the adult patient or carer of the sick child was not available for interview, and the household head identified themselves as sufficiently
knowledgeable about the illness episode to be able to answer questions about it.
DSV, drug shop vendor; mRDT, rapid diagnostic test for malaria; RDT, rapid diagnostic test.
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order to really conﬁrm that she has malaria they get to
know the truth. They [the client] are happy because
instead of going to the hospital they are being treated
nearer their home.
FGD with health workers from HC II in the intervention arm
site
P5: We now get fewer cases of malaria at our hospital.
You know what that means for our income, which is a bit
negative for us but for the community it’s okay because
they have the services nearer.
FGD with health workers in HC IV and the not-for-proﬁt
hospital
As mRDTs were introduced into drug shops, the
process of ﬁnding out about disease maintained its
ability to engender trust between the vendor and the
client and the beneﬁts of mRDTs were interpreted
through this lens. The ﬁrst quotation below links this to
a process of being able to see and then act on a disease,
while the second connected the care available at drug
shops to the larger health facilities.
Okay for me the different thing that I have seen, we have
been suffering and what made us like the hospital are
the blood tests. Yet, in these drug shops, they would
simply inject you without testing your blood to see what
type of fever it is. But for me the different thing that I
have seen now, [is that] they [DSVs] test blood. Now we
have come to completely dislike the public sector hos-
pital because that [blood testing] is what has been mostly
taking us there.
FGD with mothers in the mRDT arm of the trial
P1: The majority of us used to go to those big health
facilities but now we go there to drug shops and clinics
and they give you treatment.
P5: I think it [testing] has been good for them [the drug
shops vendors] because the majority of people have trust
in them. Previously, they would despise those clinics.
Facilitator: Previously you never used to put trust in
them. Why were you going to other health facilities in
the past?
P4: Blood, they never used to test blood.
Many Ps: Hmmm, blood
FGD with mothers in the mRDT arm of the trial
Refracted through this new logic of testing before
treating illness, previous diagnostic practices in the drug
shop were conceptually reconﬁgured. The practice of
describing and suggesting symptoms so that they could
be matched to available medicines was often recast as
guess work and was contrasted with the deﬁnitive knowl-
edge that the mRDT provided.
I think work has been simpliﬁed because those days,
before this project started, we would just try to guess
what’s going on, how to treat the patient. But after
testing, I think we know exactly what we are doing and
even the patients themselves realize it and that’s why they
come. But of course, those days they [patients] would
have that negative…what? [attitude]…but now they know
if you go there, they test you and they give you…what?…
[They] will cure you. Of course that conﬁdence has
increased in them. Ya, they are conﬁdent that they going
to get what? [That they are going to get] okay.
FGD with DSVs in the mRDT arm of the trial
The claims by DSVs and clients of the beneﬁts of
using mRDTs were signiﬁcantly broader than those
stated in the project protocol. A few clients reported
that the mRDTs in the shops they visited diagnosed
malaria, typhoid and syphilis (eg, “what came out of the
test was that my child had malaria and syphilis,” FGD
with mothers in the mRDT arm of the trial). Mostly, however,
the capacity of the tests was not speciﬁed but was
described by DSVs and their clients as creating a general
change in practice that enabled DSVs to know the
causes of and necessary treatment for ‘illness’ rather
than just identifying those patients with/without
malaria.
Ever since we started this project, it has made us treat the
patients well because before we have been treating a
person simply. A person comes, “I am suffering from
malaria.” You would touch on him, measure the tempera-
ture and then give him drugs. But now you treat some-
thing you know and he also leaves understanding that
really, they have treated me because you tested his blood.
FGD with DSVs in the mRDT arm of the trial
From the questionnaires in the mRDT arm of the trial,
just under half who had received an mRDT reported
that they had not seen the results of the test (see
table 3). Moreover, when they reported on their inter-
pretation of the role in the care-seeking process, 47% of
the 253 care seekers reported that the use of a test
either enabled the DSV ‘to know’ what was causing their
illness or fever, or ‘to treat what they know’.
Reports of the use of the mRDT to enable a deﬁnitive
diagnosis (ie, of any illness) emerged in focus groups
with DSVs and clients. In the quotation below, a mother
who attended a drug shop in the mRDT arm under-
scores how the mRDT was imagined as enabling decisive
knowledge, the effective targeting of treatment and that
this would provide better value for money than in a
system where malaria was treated presumptively.
That ﬁve hundred shillings [for the mRDT], and she
treats what she has known. Because some time back
someone could come and she (DSV) would say, “it seems
that he has malaria,” and she would prescribe different
drugs for you and she would tell you that you had to pay
this and this amount of money. But now, she takes blood
from you and she gets to know that she has tested your
blood and you have malaria and the drugs she gives you
are for malaria.
FGD with mothers in the mRDT arm of the trial
The DSV and the client quoted above also provide
details of what makes up a good visit to a drug shop,
that the client has been tested and purchased effective
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medication. The ﬁnal section of the results considers
the ways in which mRDTs acted on clients’ desires for
effective medicines and reshaped local pharmaceutical
markets in Mukono.
mRDTs increase medicine sales in drug shops
Like many of those working on the introduction of
mRDTs in other sectors of health systems in Africa, the
researchers involved in the mRDT trial in Mukono were
concerned with the ways in which DSVs would manage
negative test results. A negative mRDT could mean that
drug sellers would not make a sale, reducing their
income, and disincentivise testing among DSVs. We have
previously shown how RDT use can also affect a DSV’s
reputation.27 Negative results carry a risk of revealing
diagnostic uncertainty which could be interpreted as a
lack of knowledge and skill in managing a patient’s
illness. During the FGDs, some clients did express
concern about the ability of the test to always provide an
accurate result. During the FGDs with the DSVs,
however, concerns about negative test results were rela-
tively rare. A close look at the interpretation of the cap-
acity of the mRDT, its perceived ability to create
deﬁnitive knowledge around disease and the way in
which its introduction set a new standard for care based
on testing blood helps to make sense of this.
When DSVs described anxiety around the manage-
ment of a negative mRDT result, this was most often
linked to encounters with clients who were convinced
that they had malaria and wanted to purchase an ACT,
but what also appears to have been critical in managing
a negative result was the action taken by the DSV follow-
ing the generation of the result. Referring a client who
was not considered to be dangerously sick, especially if
the DSV did not provide any medication ﬁrst, was con-
sidered to be economically perilous and also hazardous
to their reputation and so was infrequent.27 Instead,
DSVs could act on a negative test result by providing
what was understood by the client to be effective treat-
ment. Below, two different mothers from different
focus groups explained a positive outcome of their trip
to the drug shop using mRDTs with their children. In
the ﬁrst description, the child is diagnosed with
malaria, and in the second the child tests negative to
malaria but both received an injection and other
medication.
After testing the child’s blood, she gave him an injection
and ended there. The malaria was very severe and she
gave him an injection. She even gave me tablets that were
yellow and we went back home. She even told me that I
have to give to the child plenty to drink.
FGD with Mothers in the mRDT arm of the trial
For me, I took a child there [to the drug shop] who had
diarrhoea and had fever. They tested him but there was
no malaria. They gave him drugs and syrup and they also
gave him four injections. They gave him four injections
and he got well.
FGD with Mothers in the mRDT arm of the trial
The imperative to receive medicines as an outcome of
drug shop encounters in both arms of the trial was
underscored by data from the questionnaires with care
seekers, where 100% of those interviewed during
follow-up reported having purchased some form of
medication (table 4). Unlike in the FGDs, where medi-
cines were often identiﬁed by their colour, whether they
were in tablet form, syrup, injection or crushed into a
drink, for the questionnaires clients were asked to
specify wherever possible the type of medicine that they
had purchased. In concordance with the overall ﬁndings
from the trial,15 reported sales of ACTs were substantially
lower in the mRDT arm than in the presumptive arm,
though not entirely ruling out the sale of malaria
Table 3 Client reports of perceptions and experiences with mRDT
Presumptive arm N=7 RDT arm N=247
n Per cent n Per cent
Report being shown the mRDT result
Yes 0 0 129 52.2
No 7 100 116 47.0
Did not report anything 0 0 2 0.8
Reported the mRDT result
Positive 4 57.1 142 57.5
Negative 0 0 80 32.4
Did not know 3 42.9 22 8.9
Did not report anything 0 0 3 1.2
Reported the role of the mRDT as providing
Definitive diagnosis of malaria 2 40 88 35.6
Knowledge on illness of patient 5 60 115 46.6
Did not report anything 0 0 44 17.8
mRDT, rapid diagnostic test for malaria; RDT, rapid diagnostic test.
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medicines to patients with a negative test. In the mRDT
arm of the trial, for the clients who reported having a
positive mRDT result, the majority said that they had
purchased an ACT (94%) either with (17.9%) or
without (76.4%) an antibiotic. A similar percentage to
those being treated for febrile illness in the presumptive
arm purchased an antibiotic (18%; see table 4). As one
of the FGD respondents explained, past experiences of
giving malaria medication to her son during an illness
episode continued to inﬂuence the clients’ preference
and demands for particular medicines.
Now, when you get to the health worker he tests and tells
you there is no malaria and as a result you tell him,
“Health worker, the other time you gave me these tablets
and these tablets. So, still just give me maybe Camoquine
or Chloroquine and I go and give [them to] him and I
see if he will get better.”
FGD with mothers in the mRDT arm of the trial
While the results of the FGDs suggest that there was a
good deal of polypharmacy among those testing both
positive and negative for malaria, the questionnaires sug-
gested that the range of medicines sold to clients with a
negative test result was greater than either those with a
positive result or those who had not been tested at all. It
appears that more mRDT-negative clients purchased an
antibiotic compared with mRDT-positive or untested
patients—37.6–18% and 15%, respectively. Overall, the
median amount of money spent by clients in drug shops
using mRDTs was higher than those in the presumptive
arm and the difference was marginally greater among
clients in the mRDT arm who received a negative test
result.
DISCUSSION
This paper has provided an analysis of the unintended
consequences of the introduction of mRDTs into drug
shops in Mukono district, Uganda. The study took place
alongside a cluster-randomised control trial with the
intention of providing an analysis of the broader impacts
of introducing rapid diagnostic tests in drug shops. For
the FGDs, our sampling strategy ensured that we
included a range of participants providing and seeking
care within Mukono and the semistructured interviews
were based on a random sample. In both cases, however,
the study was limited by its use of data that relied on par-
ticipants’ own accounts of their practices and experi-
ences and it is possible that both the FGD participants
and those responding to the interview questions shaped
their responses in a particular way that did not always
reﬂect actual practice. The approach could have been
enhanced by incorporating participant observation, thus
enabling researchers to observe the dynamic interactions
between test results, medicines, formulations of expert-
ise and good quality care.
To conduct the analysis, we analysed qualitative and
quantitative data, using the lens of assemblage theories
to prompt a focus on the ways in which mRDTs were
arranged and organised in relation to other objects,
people, medicines, desires, forms of regulation and every-
day practice found in these spaces. In so doing, we
suggest that the success of the intervention and its
intended effect of facilitating high rates of uptake of the
test and adherence to mRDT results was most likely con-
nected to the development of trust between the DSVs
and their clients, increased sales of unauthorised medi-
cines and the attraction of clients to drug shops during
illness episodes which would have previously resulted in a
trip to the public and private not for proﬁt formal sector.
Table 4 Treatments purchased in registered drug shops by method of diagnosis and mRDT test result
Type of drug treatment
mRDT arm
mRDT negative
N=101 (%)
mRDT positive
N=123 (%) RDT total (%)
Presumptive arm
N=246 (%)
No drugs purchased 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Antipyretic only 22 (21.8) 4 (3.3) 26 (11.6) 0 (0.0)
Other drugs only (eg, cough syrups,
deworming)
13 (12.9) 1 (0.8) 14 (6.3) 0 (0.0)
Antibiotic without any antimalarial 29 (28.7) 0 (0.0) 29 (12.9) 1 (0.4)
Other non-ACT antimalarial
treatment without antibiotic
4 (4.0) 2 (1.6) 6 (2.7) 0 (0.0)
Other non-ACT antimalarial
treatment with antibiotic
3 (3.0) 0 (0.0) 3 (1.3) 1 (0.4)
ACT without antibiotic 24 (23.8) 94 (76.4) 118 (52.7) 210 (85.4)
ACT with antibiotic 6 (5.9) 22 (17.9) 28 (12.5) 34 (13.8)
Median cost (UGX)
(minimum–maximum)
5000 (200–33 000) 4050 (300–32 000) 5000 (200–33 000) 3300 (800–45 000)
Median cost US$
(minimum–maximum)
2 (0.08–13.20) 1.62 (0.12–12.80) 2 (0.08–13.20) 1.32 (0.32–18.00)
ACT, artemisinin combination therapy; mRDT, rapid diagnostic test for malaria; RDT, rapid diagnostic test.
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Our ﬁndings that the introduction of mRDTs
appeared to make drug shops more attractive places to
seek care resonate with other observations from the
main trial. In comparison with both the exit interviews
conducted before the trial began29 and results from the
presumptive arm in the main trial, a signiﬁcantly higher
proportion of clients seen by DSVs in the mRDT arm
were parasite positive by microscopy, suggesting that
there may have been a differential change in treatment-
seeking behaviour following the introduction of mRDTs
(Mbonye, personal communication). These are different
from research ﬁndings in Kenya in which the introduc-
tion of subsidised ACTs in drug shops, rather than the
introduction of subsidised mRDTs, was considered to
impact on decision-making about where to receive
care.11 These results, however, came from a study in
which the results of mRDTs overall were reported to
have had little impact on decision-making about treat-
ment and the authors suggested that this lack of effect
on treatment seeking was likely to reﬂect their limited
impact on treatment decisions more generally.11
Our ﬁndings challenge widespread concerns that
adherence to negative mRDT results would be under-
mined in the retail sector because of the importance of
making a sale in these places.9 First, recorded adherence
to positive and negative mRDT results in relation to the
prescription of ACTs was high in the main trial ﬁnd-
ings.15 Second, questionnaires with clients found that
none had left the shop empty-handed and that costs to
clients were higher in the mRDT arm of the trial.
Reported sales of antibiotics were substantially more
common in patients who tested negative, with a slight
increase also in non-ACT antimalarials, suggesting that
the ability to sell other medications (including the
illegal sale of antibiotics and injections) was a factor in
facilitating adherence to negative test results.
Finally, the perception that mRDTs can identify other
causes of illness and not just malaria has also been
noted in other settings. In a qualitative study of patients
receiving care in public sector facilities in Ghana, the
authors were concerned that once patients learnt of its
limitations, this would lead to disappointment with the
test.30 Work on the acceptability of introducing mRDTs
into drug retail outlets in Kenya also suggests that the
capacity of mRDTs may be misinterpreted in these
settings—drug sellers there reported that their introduc-
tion would be able to remove the ‘guesswork’ from diag-
nostic practice (with no reference to malaria per se),
enabling drug sellers to target drugs more effectively.10
Whether the mRDT will appear as attractive to DSVs or
their clients if its limitations were better understood
remains an important area for further investigation.
Further research will also be needed to ascertain
whether the trust in the test as a decisive tool through
which disease can be known will change and diminish
over time and the effects that it will have on the attrac-
tion of the test to DSVs and their clients.
CONCLUSION
Interest in the potential of markets and the retail sector
in particular to deliver healthcare in low-income settings
is evident across many debates within global health.31
For those concerned with improving access to quality
assured, targeted treatment for malaria, investing in
public and donor funds in the retail sector through sub-
sidies for ﬁrst-line antimalarial medication and mRDTs
appears a logical step.9 10 32 33 While the retail sector is
constituted differently in different countries, in many
low-income countries the lack of regulatory oversight of
drug shops makes the need for holistic accounts of inter-
ventions in this sector imperative before policy change is
put into effect. In this paper, we constructed such an
analysis by drawing on Merton’s idea of the unintended
consequences of purposive action and recent theories of
assemblage. We have shown how the mRDT interacted
with the desires of care seekers for trustworthy providers
and targeted pharmaceutical cure for their illness; and
the lack of regulation of medicine sales makes the
mRDT appear more powerful than it is and drug shops
more attractive places to seek care. Once these dynamics
are taken into account, national policymakers may con-
sider that introducing mRDTs will have to go alongside
signiﬁcant concomitant improvements in the regulation
of drug shops. These could possibly be achieved
through accreditation schemes34 35 and/or through the
workings of national health insurance programmes that
may come into place in some low-income settings over
the next decade.
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